Psych Vivas · General adult psychiatry — mood disorders
Major depressive disorder — structured clinical viva
Fellowship viva covering TRD-leaning recurrent MDD, lithium augmentation, ECT indications and evidence, suicide risk, and maintenance antidepressant duration.
On this page
Study tools
Target exams
Interpretation
Reveal interpretationShowHide
This is recurrent major depression with melancholic features and incomplete response after two adequate antidepressant trials, placing him in an augmentation/specialist pathway with active suicide risk review. First confirm adequacy of prior trials (dose, duration, adherence), exclude bipolarity and substances, and complete medical work-up. Passive death wishes still require full risk assessment and safety planning with the partner as appropriate under privacy law.[4]
Lithium is a legitimate augmenter in unipolar MDD after non-response — not "only for bipolar." STAR*D included lithium versus T3 augmentation after two failed medication treatments. Discuss levels, renal/thyroid monitoring, toxicity education, and teratogenicity if relevant.[1]
ECT has robust efficacy evidence in severe depressive disorders and is appropriate to discuss proactively in severe melancholia with suicide risk and medication non-remission — frame as a medical procedure under anaesthetic with consent covering benefits, cognitive risks, cardiac/anaesthetic risks, and expected course, not as punishment or last-ditch folklore.[2]
After remission, continuation/maintenance antidepressant (and discussion of continuation ECT or lithium if used) is essential because relapse risk is high after multiple episodes; stopping soon after feeling well is a classic error.[3]
References4ShowHide
- [1]Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report Am J Psychiatry, 2006.PMID 16946176
- [2]UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis Lancet, 2003.PMID 12642045
- [3]Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review Lancet, 2003.PMID 12606176
- [4]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391